- Home
- WTRG vs JAZZ Comparison
WTRG vs JAZZ Comparison
Compare WTRG & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTRG
- JAZZ
- Stock Information
- Founded
- WTRG 1901
- JAZZ 2003
- Country
- WTRG United States
- JAZZ Ireland
- Employees
- WTRG N/A
- JAZZ N/A
- Industry
- WTRG Water Supply
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- WTRG Utilities
- JAZZ Health Care
- Exchange
- WTRG Nasdaq
- JAZZ Nasdaq
- Market Cap
- WTRG 9.6B
- JAZZ 8.1B
- IPO Year
- WTRG N/A
- JAZZ 2007
- Fundamental
- Price
- WTRG $36.56
- JAZZ $136.01
- Analyst Decision
- WTRG Strong Buy
- JAZZ Strong Buy
- Analyst Count
- WTRG 6
- JAZZ 14
- Target Price
- WTRG $43.00
- JAZZ $177.50
- AVG Volume (30 Days)
- WTRG 1.3M
- JAZZ 688.4K
- Earning Date
- WTRG 02-26-2025
- JAZZ 02-25-2025
- Dividend Yield
- WTRG 3.56%
- JAZZ N/A
- EPS Growth
- WTRG 10.16
- JAZZ 458.10
- EPS
- WTRG 1.99
- JAZZ 7.04
- Revenue
- WTRG $1,961,149,000.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- WTRG $6.83
- JAZZ $7.53
- Revenue Next Year
- WTRG $8.93
- JAZZ $6.94
- P/E Ratio
- WTRG $18.37
- JAZZ $19.42
- Revenue Growth
- WTRG N/A
- JAZZ 5.23
- 52 Week Low
- WTRG $33.18
- JAZZ $99.06
- 52 Week High
- WTRG $41.78
- JAZZ $138.27
- Technical
- Relative Strength Index (RSI)
- WTRG 59.73
- JAZZ 68.46
- Support Level
- WTRG $35.35
- JAZZ $134.56
- Resistance Level
- WTRG $36.15
- JAZZ $138.27
- Average True Range (ATR)
- WTRG 0.68
- JAZZ 3.56
- MACD
- WTRG 0.17
- JAZZ 1.17
- Stochastic Oscillator
- WTRG 90.41
- JAZZ 88.20
About WTRG Essential Utilities Inc.
Essential Utilities is a Pennsylvania-based holding company for us water, wastewater, and natural gas distribution utilities. The company's water business serves 3 million people in eight states. Nearly three fourths of its water earnings come from Pennsylvania, primarily suburban Philadelphia. Its Peoples subsidiary serves more than 740,000 gas distribution customers in Pennsylvania and Kentucky. Essential exited its noncore competitive water and energy services businesses.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.